ZYUS Life Sciences Corporation (ZYUS.V)
TSXV · CAD · Healthcare · Drug Manufacturers - Specialty & Generic
CA$0.35 (+0.00%) as of
Key statistics
- Market cap
- 28.18M
- Forward P/E
- -1.25
- EPS (TTM)
- -0.2500
- Dividend yield
- 0.00%
- 52-week range
- 0.3000 – 0.7500
- Beta
- 0.16
- Revenue (TTM)
- 374k
- Profit margin
- 0.00%
- Volume
- 115.42k
About ZYUS Life Sciences Corporation
ZYUS Life Sciences Corporation manufactures and distributes cannabinoid-based therapeutics and product candidates for medical and adult recreational. The company offers Trichomylin, a softgel capsules with fixed dose combination of cannabinoids formulated that is phase 2a clinical trial for the treatment of chronic pain in adults caused due to musculoskeletal injuries, arthritis, and cancer. It operates in Canada, the United States, Australia, and the European Union. ZYUS Life Sciences Corporation was founded in 2018 and is headquartered in Saskatoon, Canada.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Saskatoon, SK, Canada
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.